Novartis is set to release its second-quarter results on July 18. Here's what you should know:
Sales Forecast
Sales at the Swiss pharmaceutical giant are projected to reach $13.45 billion in the second quarter, based on a FactSet consensus of seven estimates. This marks an increase from the $12.78 billion reported in the same quarter of the previous year.
Net Income Forecast
The expected net income for the quarter is $3.55 billion, according to a FactSet-provided consensus based on six estimates. This shows a slight increase from the previous year's net income of $3.43 billion.
Key Growth Drivers
Kisqali - Breast Cancer Treatment
One of the key focus areas for Novartis is its breast cancer treatment Kisqali. The company is expected to provide updated sales expectations for the drug, considering recent applications to expand its use. In 2022, Kisqali generated $1.2 billion in sales and served as a significant growth driver. Analysts believe that it will continue its momentum in the second quarter.
Pluvicto - Prostate Cancer Drug
Novartis also considers its prostate cancer drug, Pluvicto, as a growth driver. It is expected to maintain strong momentum in the second quarter, according to UBS analysts.
Guidance
Jefferies analysts suggest that Novartis may revise its outlook for its innovative medicine pharmaceuticals division. If this occurs, the profit forecast for the business could be upgraded from a high single-digit outlook to low double digits.
Our Latest News
BlackRock to Acquire Global Infrastructure Partners
BlackRock Inc. is acquiring Global Infrastructure Partners (GIP) for $3 billion in cash and shares. GIP is a renowned infrastructure fund manager with a strong...
Mixed Results Expected as U.S. Stock Markets Set to Open
The U.S. stock markets are set to open with mixed results, with some promising gains in pre-market trading for certain companies, while others are experiencing...
Canada's Population Growth Reaches Historic High
Canada's population has reached a historic high, experiencing remarkable growth driven by immigration. This surge poses challenges and has implications for vari...